Does age-related adrenal DHEA decline reduce peripheral androgen production after menopause?

Age-related adrenal steroid decline (“adrenopause”) is biologically relevant after menopause because ovarian hormone production falls while peripheral tissues retain the capacity to make active androgens locally from adrenal precursors.

Clinical and hormonal evidence

• Circulating DHEA and especially DHEA-S decline with age, reducing the available systemic precursor pool for peripheral conversion to androstenedione and testosterone. This pattern is primarily age-related rather than an abrupt direct consequence of menopause.
• The link to lower testosterone signaling is plausible and directionally supported, but not deterministic: local androgen exposure depends on tissue-specific conversion rather than serum DHEA-S or testosterone alone.
• In a meta-analysis of 21 randomized trials, oral DHEA increased total testosterone overall, with larger effects at doses ≥50 mg/day and treatment durations ≥26 weeks. A small randomized trial found increased free testosterone with 25 mg/day for six months.
• In a cross-sectional postmenopausal analysis, higher DHEA-S was associated with lower odds of total testosterone <30 ng/dL (adjusted OR 0.55, 95% CI 0.47–0.63). This supports an association but cannot establish that low DHEA-S causes reduced androgen action.

Mechanistic interpretation

• DHEA-S has a relatively long half-life and functions as a circulating reservoir. Peripheral tissues can desulfate DHEA-S to DHEA, then convert it via androstenedione to testosterone through 3β-HSD and 17β-HSD/AKR1C3 activity.
• This is predominantly intracrine biology: enzyme expression within skin, adipose, bone, brain, and other tissues determines local testosterone production and signaling. Consequently, serum values may not mirror tissue exposure.

Clinical implications

• Lower adrenal precursor availability can contribute to diminished testosterone signaling after menopause, but it does not establish a clinically meaningful androgen-deficiency state or predict symptoms in an individual. Testosterone increases with DHEA have not consistently translated into improved sexual function.

Bottom line

• The claim is scientifically supported: age-related DHEA/DHEA-S decline narrows the peripheral androgen precursor pool and can contribute to lower local testosterone signaling, although the magnitude and symptom relevance vary substantially by tissue and individual.